Nanotechnology in medicine, or nanomedicine, is a relatively new field. The use of nanoparticles to diagnose and treat diseases as well as future potential to make repairs at the cellular level has spawned great interest among the pharma and biopharma industries.
CHI’s inaugural Nanotechnology in Medicine conference seeks to bring together the interdisciplinary researchers from chemistry, engineering, biology and medicine together to explore the use of nanomaterials including nanoparticles, nanodevices, nanorobots, that will revolutionize drug delivery, diagnostics and therapeutics applications.
Final Agenda
Day 1 | Day 2 | Download Brochure
THURSDAY, MAY 3
12:00 pm Registration (Commonwealth Hall)
12:35 Luncheon in the Exhibit Hall with Poster Viewing (Commonwealth Hall)
1:40 Chairperson’s Remarks
Christopher Hartshorn, PhD, Program Director, National Cancer Institute, National Institutes of Health
Taeghwan Hyeon, PhD, SNU Distinguished Professor, School of Chemical and Biological Engineering, Seoul National University
Since 1997, our laboratory has focused on large-scale synthesis and medical applications of uniform-sized nanoparticles. We reported on high-resolution MR imaging using uniform 2 nm-sized iron oxide nanoparticles in non-human primate models. We demonstrated that intravenously administered ceria nanoparticles could substantially reduce the damage from ischemic strokes, and 2 nm-sized ceria–zirconia nanoparticles can effectively reduce mortality and systemic inflammation in sepsis models.
2:20 Targeted Nanoparticles for Imaging, Drug Delivery and Biosensing
Paul Millner, PhD, Professor of Bionanotechnology, School of Biomedical Sciences, University of Leeds
Functionalising nanoparticles with antibodies or “synthetic antibodies” (Affimers) brings a range of potential biomedical applications. mAb addressed fluorescent silica nanoparticles locate efficiently to colorectal cancer xenographs. The same functionalisation of lanthanide doped nanoscrystals allows fluorescence up-conversion base quantification of medical analytes with nM to pM sensitivity. Finally, functionalization of lipidic nanoparticles should allow targeting of low cost anti-cancer agents. In all cases, correct design of surface chemistry minimizes non-specific interactions.
2:50 Assemble Nanoparticles in vivo for Cancer Imaging and Treatment
Jianghong Rao, PhD, Professor, Radiology and Chemistry (courtesy), Molecular Imaging Program, Cancer Biology and Biophysics Programs, Stanford University
3:20 Sponsored slot cancelled - please attend an alternative presentation in one of the other 6 concurrent conference sessions.
3:50 Networking Refreshment Break (Harbor & Mezzanine Level)
4:20 Biomimetic Nanotechnology Enhances Surface Detection of Circulating Tumor Cells in Peripheral Blood from Head and Neck Cancer Patients
Seungpyo Hong, PhD, Professor, Pharmaceutics, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison
We report the development of a biomimetic CTC capture chip that utilizes multi-antibody, multivalent binding, and biomimetic cell rolling concepts to significantly improve overall CTC capture sensitivity and specificity. We demonstrated that the combination of multi-antibody and multivalent binding improves CTC capture sensitivity, and the cell rolling effect improves CTC capture specificity (up to 38%). Our data also suggest CTC can be an important biomarker for head and neck cancer disease monitoring and surveillance.
4:50 Digital Resolution Biomolecule Sensing by Photonic Resonator Absorption Microscopy (PRAM) with Plasmonic Nanoparticle Tags
Brian T. Cunningham, PhD, Willett Professor of Engineering, Director, Micro and Nanotech Lab, Electrical and Computer Engineering, University of Illinois at Urbana -Champaign
Using gold nanoparticles that are engineered to match the resonant wavelength of a photonic crystal biosensor surface, we have developed a new form of microscopy called Photonic Crystal Absorption Spectroscopy (PRAM) that enables individual adsorbed nanoparticles to be dynamically counted with high signal-to-noise ratio. We utilize PRAM for counting virus particles, miRNA, and proteins for application in simple, rapid, and ultrasensitive diagnostics with digital analyte resolution that does not require enzymatic amplification.
5:20 End of Day
5:20 Registration for Dinner Short Courses (Commonwealth Hall)
Day 1 | Day 2 | Download Brochure
FRIDAY, MAY 4
8:00 am Morning Coffee (Harbor Level Lobby)
8:30 Chairperson’s Remarks
Paul Millner, PhD, Professor of Bionanotechnology, School of Biomedical Sciences, University of Leeds
8:35 Development of Novel Antibody Directed Nanotherapeutics for the Treatment of Solid Tumors
Daryl Drummond, PhD, Head of Research, Merrimack Pharmaceuticals
Antibody targeted nanotherapeutics offer the promise of multiple levels of targeting due to the combination of size-related delivery to solid tumors via the EPR effect when combined with antibody-specific penetration in solid tumors. Engineered lipid based delivery systems have been clinically validated, and next generation nanotherapeutics with antibody targeting are currently being explored in early Phase clinical trials.
9:05 Enabling and Expanding the Use of Microbial-Derived Biologics through the Use of Tolerogenic Nanoparticles
Kei Kishimoto, PhD, CSO, Selecta Biosciences
The pharmaceutical industry has exploited the microbiome to create small molecule drugs to a wide variety of diseases. However broad use of microbial-derived biologics or ‘xenobiologics’ is limited by immunogenicity. Here we describe the use of tolerogenic nanoparticles to create improved and novel xenobiologic drugs. I will present case examples of applying tolerogenic nanoparticles to a fungal-derived uricase enzyme, in Phase 2 clinical trials for the treatment of gout, a bacterial-derived immunotoxin for cancer therapy, and adeno-associated virus for gene therapy.
9:35 Panel Discussion : Targeted Nanoparticle-Mediated Drug Delivery
Moderator: Paul Millner, PhD, Professor, Bionanotechnology, School of Biomedical Sciences, University of Leeds
Panelists:
Jan E. Schnitzer, MD, Director, Professor of Cellular and Molecular Biology, Proteogenomics Research Institute for Systems Medicine (PRISM)
Daryl Drummond, PhD, Head of Research, Merrimack Pharmaceuticals
- Potential for minimizing off-target drug dose
- Potential for delivering generic cytotoxins in a targeted manner (affordable medicine for the developing world)
- Possibility of multifunctional particles (delivery and imaging)
- Range of nanoparticle material ranging from hydrophilic to hydrophobic
10:05 Networking Coffee Break (Harbor & Mezzanine Level)
10:35 Safe and Effective Nanomedicines for Cancer and Inflammatory Diseases
Hayat Onyuksel, PhD, Professor, Biopharmaceutical Sciences, University of Illinois
Application of nanotechnology to drug delivery provides targeted therapy, which results in higher efficacy at the site of action, and significantly lower drug toxicity to the healthy tissues for a given dose. Using phospholipid micelles as nanocarriers (15nm) our laboratory has developed several nanomedicines that were effective and safe on animal models of cancer and inflammatory diseases. In this talk the parameters required to develop successful nanomedicines will be presented.
11:05 A Modular Platform for Targeted RNAi Therapeutics Using Biologically-Lipidated Antibodies
Itai Benhar, PhD, Professor, Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel Aviv University
We present a modular platform to target specific cell types using siRNA loaded lipid nanoparticles (LNP) coated with oriented, targeting antibodies. The antibodies are non-covalently bound to a membrane-anchored lipoprotein that recognizes their Fc domain. In one example, intravenously injected anti-Ly6C-coated LNP encapsulating TNF siRNAs were taken up selectively by Ly6C+ monocytes and activated tissue macrophages, suppressed TNF-alpha expression in the colon and ameliorated inflammatory bowel disease symptoms in a DSS-induced colitis mouse model.
11:35 Smart, Multifunctional Liposomal Nanoformulation for Treating Fabry and Other Rare Diseases
Jose Luis Corchero Nieto, PhD, Senior Scientist, Nanobiotechnology Group, CIBER-BBN, Institute of Biotechnology and Biomedicine, Universitat Autonoma de Barcelona
Preparation of new liposomal formulations by DELOS-SUSP, based on the depressurization of CO2-expanded liquid organic solutions, has shown the great potential of this methodology to prepare nanomaterials with therapeutic interest. Here, we will discuss the preparation and characterization of nanovesicles containing therapeutic proteins for treatment of rare diseases, and their development, up to the end of the regulatory preclinical phase, under the frame of the European “Smart-4-Fabry” project.
12:05 pm Targeted Ultrasmall Silica Nanoparticles as Next-Generation Treatment Tools for Drug Delivery
Michelle Bradbury, MD, PhD, Co-Director, MSK-Cornell Ctr for Translation of Cancer Nanomedicines and Prof, Radiology, Memorial Sloan Kettering Cancer Center
Advances in nanotechnology have fueled a paradigm shift in targeting and safely delivering drugs in conjunction with image-directed approaches. The ability to flexibly adapt the formulation of clinically-promising drugs to improve their physicochemical and/or biological properties, in combination with particle probes and metabolic imaging tools, will be important to quantify and establish suitable clinical trial endpoints. The future success of molecular medicine rests upon improved clinical trial designs addressing these issues.
12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on your Own
1:05 Networking Refreshment Break (Harbor & Mezzanine Level)
1:35 Chairperson’s Remarks
Brian T. Cunningham, PhD, Willett Professor of Engineering, Director, Micro and Nanotech Lab, Electrical and Computer Engineering, University of Illinois at Urbana -Champaign
1:40 TALK CANCELLED - SPEAKER FAMILY EMERGENCY
Nanoemulsion Technology for Intranasal Immunization Facilitates Vaccine Uptake by Antigen Presenting Cells at Mucosal Tissues, Induces Innate Immunity, and Enhances Mucosal Immunity
Tarek Hamouda, MD, PhD, Senior Director Clinical Development, NanoBio Corp.
Nanoemulsion facilitated and enhanced the uptake of antigens by epithelial cells and other antigen-presenting cells such as mucosal dendritic cells. When NE-formulated vaccines were administered mucosally (intranasal or intravaginal), they elicited a balanced Th1/Th2 immune responses. Intranasal immunization with Ne-formulated vaccines elicited a high Th17 responses and homed immune memory B-cells (IgG and IgA producing cells) to respiratory and genital mucosal tissues. In conclusion, nanoemulsion can play a major role in combating serious infectious diseases.
2:10 Designing Nanoparticles to Actively and Specifically Penetrate Solid Tumors
Jan E. Schnitzer, MD, Director, Professor of Cellular & Molecular Biology, Proteogenomics Research Institute for Systems Medicine (PRISM)
Nanocarrier utility in drug delivery has been questioned. Current nanoparticles can only move across endothelial cell barriers passively. Their size and RES uptake limit solid tumor penetration and targeting. We have discovered an active transvascular delivery system and applied it to pump nanoparticles carrying imaging and therapeutic cargo across endothelium and specifically into solid tumors within one hour of intravenous injection. Tumor-specific imaging, size constraints and therapeutic impact will be addressed.
2:40 Synthetic Nanocarriers for the in situ Programming of Disease-Specific T Cells
Matthias Stephan, MD, PhD, Associate Member, Fred Hutchinson Cancer Research Center, Associate Professor, University of Washington
Despite the obvious advantages afforded by targeted T cell therapies, the complexity and costs involved in producing genetically-modified lymphocytes remain major obstacles to their implementation as standard-of-care. In this talk, I will introduce a new injectable nanoreagent our group developed that that can quickly program tumor- or pathogen-recognizing capabilities into circulating T cells without the need for laboratory manipulations.
3:10 Bioresponsive Nanotechnologies for Systemic RNA Delivery to Tumors
Jinjun Shi, PhD, Assistant Professor, Center for Nanomedicine, Brigham and Women’s Hospital, Harvard Medical School
Biologically responsive nanotechnologies have attracted tremendous attentions for controlled delivery of therapeutic molecules and the development of precision medicines. Dr. Shi and his laboratory have developed various bioresponsive nanoparticle platforms to tackle the challenges associated with systemic siRNA delivery to tumor cells, such as enzymatic degradation, poor pharmacokinetics, and insufficient tumor penetration, cellular uptake and endosomal escape. In a recent effort, nanoparticle-mediated systemic delivery of therapeutic mRNA has also been demonstrated in various tumor models.
3:40 End of Conference
Day 1 | Day 2 | Download Brochure